/ PORTFOLIO

San Diego, CA

Avalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. Avalyn is rapidly advancing this asset, as well as additional pipeline candidates for treating IPF and other severe respiratory diseases.

logo-rivervest

© Copyright RiverVest® All Rights Reserved.